We are live on ! Find out more
NRXPW

NRX Pharmaceuticals Warrant
NRXPW

Delisted

NRXPW was delisted on the 22nd of May, 2026.

Back to rankings

19 hedge funds and large institutions have $669K invested in NRX Pharmaceuticals Warrant in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

0% more funds holding

Funds holding: 19 → 19 (0)

4% less capital invested

Capital invested by funds: $696K → $669K (-$27.1K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
19
Holders Change
–
Holders Change %
0%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
1
Calls
$17K
Puts
–
Net Calls
+$17K
Net Calls Change
+$17K

Top Buyers

Rank Fund Capital Flow
1
VOAM
Vertex One Asset Management
British Columbia, Canada
+$39K
2
Walleye Trading
Walleye Trading
New York
+$98

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$19.7K
2
BI
Bulldog Investors
New Jersey
-$8.31K
3
PC
Periscope Capital
Ontario, Canada
-$3.04K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$361K – – –
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$64K – – –
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$38K – – –
VOAM
4
Vertex One Asset Management
British Columbia, Canada
$34K +$39K +200,000 New
VAS
5
VR Advisory Services
Cayman Islands
$27K – – –
OAM
6
Oxford Asset Management
United Kingdom
$21K – – –
RCM
7
Rivernorth Capital Management
Florida
$20K – – –
AA
8
AQR Arbitrage
Connecticut
$17K – – –
PC
9
Periscope Capital
Ontario, Canada
$15K -$3.04K -15,584 -14%
6CM
10
683 Capital Management
New York
$14K – – –
YCM
11
Yakira Capital Management
Connecticut
$14K – – –
BI
12
Bulldog Investors
New Jersey
$12K -$8.31K -42,620 -38%
GCL
13
Glazer Capital LLC
New York
$11K – – –
CAC
14
Cowen and Company
New York
$10K +$11.4K +58,586 New
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$5K – – –
LIM
16
Longfellow Investment Management
Massachusetts
$2K – – –
Walleye Trading
17
Walleye Trading
New York
$2K +$98 +500 +4%
HIM
18
HGC Investment Management
Ontario, Canada
$1K – – –
UBS Group
19
UBS Group
Switzerland
$1K – – –
KPF
20
K2 Principal Fund
Ontario, Canada
– -$19.7K -101,200 Closed

NRXPW Hedge Fund Activity: Q3 2019 in Review

19 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q3 2019, worth a combined $669K — down 3.9% from $696K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new NRXPW positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Vertex One Asset Management, opening a new position worth an estimated $39K. The largest seller was K2 Principal Fund, exiting entirely with an estimated $19.7K sold.

  • 19 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $669K of NRX Pharmaceuticals Warrant stock for Q3 2019, down 3.9% quarter-over-quarter.
  • 2 funds opened new NRX Pharmaceuticals Warrant positions in Q3 2019 and 1 closed out, a net change of +1 holder.
  • The largest NRX Pharmaceuticals Warrant buyer in Q3 2019 was Vertex One Asset Management, an estimated $39K added.
  • The largest NRX Pharmaceuticals Warrant seller in Q3 2019 was K2 Principal Fund, an estimated $19.7K sold.

Based on aggregated 13F filings for Q3 2019.